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A B S T R A C T The molecular pathology of the porphobilinogen (PBG)-deaminase deficiency in heterozygotes for acute intermittent porphyria (AIP) was investigated by means of biochemical and immunologic techniques. The stable enzyme-substrate intermediates ( A, B, C, D, and E) of PBG-deaminase were separated by anion-exchange chromatography of erythrocyte lysates from heterozygotes for AIP and normal individuals. In normal lysates, the intermediates eluted in a characteristic pattern with decreasing amounts of activity (A > B > C > D > E), the combined A and B intermediates representing >75% of total recovered activity. In contrast, two different profiles were observed in lysates from heterozygotes for AIP. In most heterozygotes, the elution profile was similar to that of normal individuals, but each intermediate was reduced -50%. A second profile in which the C intermediate had disproportionately higher activity than the A or B intermediates was observed in asymptomatic heterozygotes with high urinary levels of PBG (>5 ,ug/ml) as well as in heterozygotes during acute attacks. These findings suggested that the C intermediate (the dipyrrole-enzyme intermediate) may be rate limiting in the stepwise conversion of the monopyrrole, PBG, to the linear tetrapyrrole, hydroxymethylbilane. To investigate further the nature of the enzymatic defect in AIP, sensitive immunotitration and immunoelectrophoretic assays were developed with the aid of a rabbit anti-human PBG-deaminase IgG preparation produced against the homogeneous enzyme. Equal amounts of erythrocyte lysate activity from 32 heterozygotes for AIP from 22 unrelated families and 35 normal indiviReceived for publication 12 December 1980 and in revised form 17 (AIP) ,' a dominantly inherited inborn error of heme biosynthesis, is characterized by the half-normal activity of porphobilinogen (PBG)-deaminase (EC 4.3.1.8) (1, 2) . The enzymatic deficiency has been demonstrated in erythrocytes 1 (1) (2) (3) (4) (5) (6) , liver (7, 8) , cultured skin fibroblasts (9) , amniotic cells (10) , and cultured lymphoblasts (11) from heterozygotes for AIP. Comparison ofthe physical and kinetic properties of the PBG-deaminase activity in erythrocyte lysates from heterozygotes for AIP and normal individuals have shown essentially identical electrophoretic mobilities (3), heat denaturation profiles (12) , and apparent Michaelis constant (Ki) values (5, 12) . In addition, mitogen-stimulated lymphocytes from heterozygotes for AIP induced only 50% of the activity detected in mitogen-treated lymphocytes from normal individuals (11) . Although these studies are consistent with a structural gene mutation (1) , it has been suggested that the half-normal levels of PBG-deaminase activity in AIP may be due to a regulatory gene defect (11) , but immunologic evidence supporting a structural mutation of the PBG-deaminase gene in AIP, i.e., the demonstration of noncatalytic crossreactive immunologic material (CRIM), has not been reported to date.
Increasing attention has focused on the characterization of PBG-deaminase from various sources (13) (14) (15) (16) (17) (18) (19) and the mechanism by which this monome, zc enzyme (-37,000 mol wt) converts the monopyrrole substrate, PBG, to the final tetrapyrrole product, uroporphyrinogen L (20) (21) (22) (23) (24) (25) (26) (27) . Recently, we reported the first purification of homogeneous PBG-deaminase from human erythrocytes (27) . Anion-exchange chromatography of the purified enzyme resolved the activity into five forms, designated A, B, C, D, and E. Interconversion studies and experiments with [3H]PBG demonstrated that the five forms were stable enzyme-substrate intermediates in the sequential condensation of four PBG molecit es into the tetrapyrrole, uroporphyrinogen L (27) . 'i lhe occurrence of these stable PBG-deaminase intermediates was independently confirmed by 13C-nuclear magnetic resonance studies that demonstrated the order of assembly of the four pyrrole rings and established that the end-product of the PBG-deaminase reaction was the linear tetrapyrrole, hydroxymethylbilane, which nonenzymatically cyclized to form the uroporphyrinogen I isomer (22) (23) (24) (25) . Fig. 1 illustrates the current concept of the stepwise enzymatic conversion of the monopyrrole, PBG, to the tetrapyrrole, hydroxymethylbilane. In the presence of uroporphyrinogen III cosynthase, hydroxymethylbilane was shown to be enzymatically converted into the uroporphyrinogen III isomer, the precursor of heme, cobalamins, and the cytochromes (25, 26) .
In light of the discovery of the stable PBGdeaminase enzyme-substrate intermediates, an investigation was undertaken to characterize the molecular pathology of the enzymatic defect in AIP biochemically and immunologically. We report here (a) the activity profiles of enzyme-substrate intermediates in erythrocyte lysates from normal individuals and hetero- Humelani suibjects a ad specimen collection 32 heterozygotes for AIP were studied; the diagnosis of each was biochemically documented by demonstration of decreased PBG-deaminase activity in erythrocyte lysates. These stubjects were from 22 uinrelated fiamiilies representing at least 10 different ethnic backgrounds or countries of origin. Heparinized blood was collected from each heterozygote and 35 age-and sex-matched normal individuals. Following centrifugation at 2,500 g, the erythrocytes were removed, washed twice with 0.9% NaCl, and then either used immediately or stored at -20°C.
Assays
PBG-deaminase assay. Enzymatic activity was determined by the measurement of uroporphyrin fluorescence as previously described (27) . One unit of enzymatic activity equals 1 nmol of uroporphyrin produced per hour at 37°C.
Protein assay. Protein concentrations were determined by the fluorescamine procedure as previously described (28 A 0.9 x 30-cm column of DEAE-cellulose that had previously been acid and base washed was equilibrated with the same buffer used for dialysis (27) . Each dialyzed erythrocyte lysate was applied to the column at a flow rate of 1.0 ml/min, and then 60 ml of buffer was passed through the column. PBG-deaminase enzyme-substrate intermediates were eluted as peaks of enzymatic activity using a 400-ml linear NaCl (0 to 0.11 M) gradient. Fractions (2.0 ml) were collected and 0.5 ml was assayed for PBG-deaminase activity at 37°C for 2 h.
Isoelectric focusing. Horizontal agarose slab gels and the Pharmacia system were used for isoelectric focusing of the PBG-deaminase intermediates in accordance with the manufacturer's instructions. Gels were prepared by heating a mixture of 0.3 g Agarose IEF (Pharmacia), 3 .6 g sorbitol, and 27 ml distilled water in a boiling water bath. After cooling to 75°C, 1.9 ml of pH 5-8 Pharmalyte ampholines was added. The mixture was then pouired into a horizontal casting frame (11.4 x 22.5 cm with Gelbond film backing) that had been preheated to -60°C using a portable hairdryer. Gels were either allowed to harden at least 1 h at 40C or stored overnight at 4°C in a moist chamber. Before isoelectric focusing, erythrocyte lysates were heated at 600C for 1 h, centrifuged at 100,000 g for 20 min, and then aliquots of the supernate (50-100,ll) were pipetted onto Whatman no. 17 paper strips (Whatman, Inc., Clifton, N. J.), which were placed 1 cm from the cathode. The cathode contained 1 M NaOH and the anode, 0.05 M H2S04. Focusing was carried out for 2.5 h at 10 W (constant power) at 4°C. The filter paper strips were removed after the hemoglobin had migrated about 1 cm from the origin. Upon completion, a 0.5-cm strip was removed from the gel, cut into 1-cm pieces, soaked in distilled H2O, and the pH of the leached ampholytes was determined. The gel was overlaid with Whatman no. 3MM filter paper saturated with 0.5 mM PBG, covered with polyvinylchloride film, and incubated at 37°C for 90 min. The overlay was removed, the gel was exposed to ultraviolet light for 10 min to oxidize the uroporphyrinogen to uroporphyrin, and the red fluorescent bands of PBG-deaminase activity were rapidly photographed under UV light with Polaroid type 58 film (Polaroid Corp., Cambridge, Mass.) with a Wratten no. 4 filter (Eastman Kodak Co., Rochester, N. Y.).
Crossed-immunoisoelectric focusing of the separated PBGdeaminase intermediates was performed by removing an unstained lane from the focusing gel and pouring an antibodycontaining agarose gel such that the individual intermediates could be electrophoresed directly into it. Rocket immunoelectrophoresis was carried out as described below, except that a larger gel (5.0 x 7.5 cm) containing 8 ml of 1% agarose and 40 ,ul of antiserum was used.
Immunologic studies
Purification of PBG-deaminase from human erythrocytes. Human PBG-deaminase was purified to homogeneity as previously described by Anderson and Desnick (27) . The preparation was routinely stored after the Sephadex G-100 step in the presence of 1.0 mM DL-dithioerythritol. When individual enzyme-substrate intermediates were required, the preparation was subjected to the final DEAE-cellulose chromatographic step (27) .
Production of rabbit anti-human PBG-deaminase IgG. New Zealand rabbits were injected intradermally and intramuscularly with 150 ,ug of homogeneous human PBGdeaminase A in a 1:1 suspension of Freund's complete adjuvant. Booster injections of 150, 100, and 75 ,ug were given at 1-mo intervals. The titers of rabbit anti-human PBGdeaminase were determined by immunotitration. The IgG fraction from the pooled rabbit sera was partially purified by the method of Harboe and Ingeld (29) . The antibody was precipitated by the addition of 4 vol of saturated ammonium sulfate, pH 7.0, to 6 vol of rabbit serum. After stirring 2 h at 4°C, the solution was centrifuged at 2,500 g for 20 min and washed twice with 1.5 M ammonium sulfate, pH 7.0. Hemoglobin and albumin were in the supernate and >90% of the IgG was recovered in the pellet. The pellet was resuspended in distilled water and extensively dialyzed against 5 mM potassium phosphate buffer, pH 7.4, containing 0.9% NaCl. The IgG fraction was divided into 1.5-ml aliquots and stored at -20°C.
Immunotitration of anti-human PBG-deaminase. Homogeneous PBG-deaminase A (40 ng of enzyme diluted in bovine serum albumin to 50 ,ul having a final protein concentration of40 mg/ml) and 50 ,u of rabbit anti-PBG-deaminase IgG (in serial dilutions) were mixed and incubated at 370C. After 30 min, 50 ,ul of goat anti-rabbit IgG was added and the mixture was incubated at 37°C for 30 min. To insure quantitative precipitation of the anti-PBG-deaminase antibodies, the samples were left overnight at 4°C. The mixtures were then centrifuged at 4,000 g for 15 min. The activity in the supemate was determined by the standard assay described above. For immunotitration of the immunoreactive PBG-deaminase in erythrocyte lysates from normal and AIP heterozygotes, the lysate activities were equalized and then either 50-or 25-Al aliquots were titrated against the antibody as described above.
Quantitation of CRIM in normal controls and individuals with AIP Sample preparation. Erythrocytes from normal individuals and heterozygotes for AIP were lysed by the addition of 3 vol of 1.0 mM sodium phosphate buffer, pH 7.6, containing 1 mM DL-dithiothreitol, 1 mM MgCl2, and 0.05% Triton X-100. The lysate was centrifuged at 30,000 g for 20 min and the supemate was removed and used for assays of protein and PBG-deaminase activity. Samples were diluted and then reassayed to ensure that all lysates contained equal enzymatic activity before rocket immunoelectrophoresis.
Rocket immunoelectrophoresis. The rocket immunoelectrophoretic system for human PBG-deaminase was developed as a modification of standard methods (30) . A 1% agarose solution was prepared in 0.06 M Tris-barbital buffer, pH 8.8, and 6.0 ml was poured into a 5 x 7.5-cm plate in the center of which a 0.4 x 2.5 x 7-cm double thickness glass microscope slide had been placed. After the agarose had gelled, the slide was removed and 4.0 ml of a 1% agarose solution containing 15 ul ofrabbit anti-human PBG-deaminase was poured into the center area. The agarose had been cooled to 60-65°C before antibody was added.
For routine immunoelectrophoresis of erythrocyte lysates, 11 2-mm wells were cut into the lower portion of the antibody-containing gel and 7-,ul samples were added to each well. Cotton wicks were used to make contact between the gel and the 0.06 M Tris-barbital electrophoresis buffer. The plate was electrophoresed for 4 h at a constant current of 30 mA. Following electrophoresis, the gel was thoroughly washed in 0.9% NaCl for 10-12 h with several changes and then overlayed with 300 ul of sheep anti-rabbit peroxidaseconjugated IgG that previously had been diluted 1:2 with 0.9% NaCl. The plate was incubated at room temperature in a moist chamber to prevent drying. The gel was again washed with 0.9% NaCl for at least 8 h and then stained for peroxidase. The staining solution was 25 mg diaminobenzidine tetrahydrochloride dissolved in 50 ml 0.1 M Tris/ HCI buffer, pH 7.6, containing 0.15 ml of 3% hydrogen peroxide. After the gel and staining solution were allowed to react for 20 min at room temperature, the gel was photographed and stored in 0.9% NaCl. The peroxidase reaction mixture stained the gel brown; rockets appeared white against the brown background. Crossed immunoisoelectric gels were stained with Coomassie Brilliant Blue R-250 and destained as previously described (31) .
RESULTS
PBG-deaminase enzyme-substrate intermediates in erythrocytes. Fig. 2 shows representative DEAEcellulose chromatographic elution profiles of the PBGdeaminase enzyme-substrate intermediates in erythrocyte lysates from normal individuals and heterozygotes for AIP. In 12 normal individuals the activity of the PBG-deaminase A and B forms always contained >75% of total recovered activity ( Fig. 2A) . Occasionally, the C intermediate partially separated into two overlapping peaks. Two different elution patterns were observed in AIP heterozygotes ( Fig. 2B and C (Fig. 2C) . In these heterozygotes, there was a disproportionate increase in the activity of the C intermediate, particularly when com-pared with the A and B activities. In two heterozygotes, erythrocyte samples were obtained during an acute attack and subsequently during remission. Both heterozygotes had type 2 profiles (Fig. 2C) during the acute attack and type 1 elution patterns (Fig. 2B ) in remission; these profiles also correlated with the level of urinary PBG excretion.
Characterization ofanti-PBG-deaminase. Anti-human PBG-deaminase was raised in New Zealand rabbits immunized with the homogeneous A intermediate. The titer of immune sera that resulted in 50% precipitation of purified enzyme was -1:150. This immune sera was ammonium sulfate precipitated at 40% saturation to remove hemoglobin and albumin (29) . After resuspension and dialysis, the anti-PBGdeaminase IgG preparation had a titer of -1:80. With increasing antibody concentration, PBG-deaminase activity was depleted from the supernate and recovered in 'the pellet. This antibody preparation was shown to be specific for purified human PBG-deaminase by Ouchterlony double immunodiffusion and competitive immunoprecipitation studies. Immunodiffusion showed a single arc of identity between the homogeneous enzyme and erythrocyte lysates when stained for protein and activity using PBG as substrate (Fig. 3) .
Evaluation of CRIM in AIP families. A rocket immunoelectrophoretic system was used to quantitate immunoreactive PBG-deaminase protein. As shown in Fig. 4, 3-15 ng of homogeneous enzyme, in 3-ng increments, gave proportionate increases in rocket peak height. Similarly, increasing activity in erythrocyte lysates resulted in proportionate increments. Equal activities of each PBG-deaminase enzyme-substrate (Fig. 5) . For each normal individual and each heterozygote from these 21 AIP families, the amount of activity applied corresponded to the amount of CRIM detected. Thus, the mutations in the AIP heterozygotes from these families were designated as CRIM negative. However, in a family of Basque ancestry, the amount of CRIM was consistently greater in all seven AIP heterozygotes studied (Fig. 6 ). These findings demonstrated the presence of noncatalytic, immunologically cross-reactive material (CRIM-positive) in this AIP family of Basque ancestry.
Consistent with these results, competitive immunotitration studies (Fig. 7) revealed the presence of noncatalytic PBG-deaminase protein in the AIP heterozygotes from the Basque family (Fig. 7A ) and the absence of noncatalytic CRIM in the other AIP families studied (Fig. 7B) . When samples containing equal activities of homogeneous PBG-deaminase or PBGdeaminase in erythrocyte lysates from normal individuals or the CRIM-positive family were immunotitrated, the antibody dilutions required to precipitate 50% of the activity in the supernates were -1:112, 1:112, and 1:68, respectively. A mixture containing equal activities from a CRIM-positive and a normal lysate required on antibody dilution of -1:86 for 50% immunoprecipitation. On the basis of these findings, the estimated amount of immunoreactive protein in the CRIM-positive variant was 1.65-fold that in normal FIGURE 5 Rocket immunoelectrophoresis of PBG-deaminase in erythrocytes from CRIM-negative AIP heterozygotes and normal individuals. Equal enzymatic activities were applied to the gel. No differences in rocket peak heights of immunoreactive enzyme were observed for equal activities of erythrocyte PBG-deaminase from normals (odd channels) and the (CRIM-negative) AIP heterozygotes (even channels).
A-1 A-2 A-3 A-4 A-5 FIGURE 6 Rocket immunoelectrophoresis of PBG-deaminase in erythrocytes from CRIM-positive AIP heterozygotes. Equal enzymatic activity in erythrocyte lysates from heterozygotes of an AIP kindred of Basque ancestry (Al-A5, even lanes) and normal individuals (odd lanes) were applied. The rocket peak heights of immunoreactive enzyme from each AIP heterozygote was increased when compared with those in lysates from normal individuals or unaffected members of this kindred (not shown).
lysates, assuming identical antibody avidities. In contrast, when equal amounts of erythrocyte lysate activity from a CRIM-negative AIP heterozygote and a normal individual as well as purified enzyme were immunotitrated, essentially the same antibody dilution was required to precipitate 50% of activity from each (Fig. 7B) , which indicates a direct correspondence between activity and immunotitratable enzyme protein.
Characterization of the noncatalytic PBG-deaminase in the CRIM-positive family. The Km and stability of the PBG-deaminase activity in erythrocyte lysates from the CRIM-positive AIP heterozygotes were compared with those of GRIM-negative AIP heterozygotes and normal individuals. The Km values in all three sources were essentially the same (-10 ,tM). However, the immunoreactive PBG-deaminase in the CRIM-positive heterozygotes remained stable after heating the lysate for 30 min at 60°C, whereas the immunoreactive enzyme protein in normal and CRIM-negative AIP lysates was in each case decreased -15% after 30 min of heat treatment. Agarose isoelectric focusing demonstrated no significant differences in the isoelectric points of homogeneous human PBG-deaminase and PBG-deaminase in erythrocyte lysates from normal, CRIM-positive, or CRIM-negative individuals. Routinely, five bands of enzymatic activity were visualized with pI of -6.4, 6.1, 5.8, 5.5, and 5.3. When samples were subjected to isoelectric focusing in the first dimension and then to crossed-immunoelectrophoresis in the second dimension, no evidence for a mutant protein with different isoelectric properties was obtained; a precipitin line of identity, which corresponded to each of the five PBG-deaminase intermediates, was observed in lysates from normal individuals and CRIM-negative and CRIM-positive AIP heterozygotes ( Fig. 8 ; CRIM-negative AIP lysate not shown). Lysates (Fig. 8) .
To fu-rther estimate the amount of PBG-deaminase protein present in the CRIM-positive heterozygotes, proportionate increments of normal PBG-deaminase activity were compared with a constant amount of activity from a CRIM-positive heterozygote by rocket immunoelectrophoresis. As shown in Fig. 9 , the amount of CRIM in this heterozygote corresponded to -1.6 U of normlal imimunliioreactive protein, which gives a CRIM-activity ratio of 1.6 compared with 1 To analyze the nature of the enzymatic defect in the CRIM-positive family, the enzyme-substrate intermediates were isolated from erythrocyte lysates of a normal individual and a CRIM-positive heterozygote by DEAE-cellulose chromatography and equal activities of the A, B, C, and D forms were applied to the immunoelectrophoretic gels. As shown in Fig. 10 , each of the intermediates from the CRIM-positive heterozygote had elevated levels of immunologically crossreacting material when compared with an equal airmount of activity of the respective normal intermediate, the B form being present in the greatest amount.
DISCUSSION
Recognition that PBG-deaminase catalyzes the formation of uroporphyrinogen I via stable enzyme-substrate intermediates (Fig. 1) (27) suggested that the characterization of these forms might provide insight into the molecular nature of the dominantly inherited enzymatic defect in AIP. Therefore, the PBG-deaminase intermediates in erythrocyte lysates from heterozygotes for AIP and normal individuals were biochemically and immunologically characterized. Following DEAE-cellulose chromatography of erythrocyte lysates, the activity pattern of the enzyme-substrate intermediates for most AIP heterozygotes was similar to that observed in normal individuals. When, however, lysates from the same number of erythrocytes were chromatographed, the activity of each intermediate was approximately half that of the corresponding normal intermediate (type 1 pattern), consistent with expression of only the normal allele. In AIP heterozygotes who had high urinary and circulating concentrations of PBG (e.g., during an acute attack), the dipyrrole intermediate was disproportionately increased (type 2 pattern), which suggests that this intermediate was either the most stable or the rate-limiting step in the conversion of PBG to uroporphyrinogen I, at least in erythrocytes. When the pattern of erythrocyte intermediates was studied before, during, and after an . . ' . 'This would suggest that the induction of hepatic 8-aminolevulinate synthase during an acute attack resulted in the increased production of 8-aminolevulinic acid and PBG (32) that gained access to the erythrocyte where the PBG became bound to the PBGdeaminase (33) . Thus, the patterns of the PBGdeaminase intermediates in AIP heterozygotes were consistent with the expression of the normal allele and were dependent, in part, on the substrate concentration in erythrocytes.
Immunologic characterization of the enzymatic defect revealed genetic heterogeneity in AIP. (Fig. 7) . Thus, the mutation in these 21 unrelated AIP families was designated as CRIM negative.
In contrast, when erythrocyte lysates from all seven heterozygous members (whose clinical manifestations were indistinguishable from the above CRIM-negative heterozygotes) of an AIP kindred of Basque ancestry were subjected to rocket immunoelectroIsoelectric focusing and crossed-immunoelectro-phoresis (Fig. 6) and immunotitration (Fig. 7) , non-PBG-deaminase in erythrocyte lysates from nor-catalytic immunoreactive protein was observed. The (Fig. 10) . Each of the intermediates from the CRIM-positive AIP heterozygotes had elevated An unexpected result was the fact that in 21 of the 22 unrelated AIP families, the PBG-deaminase mutation was CRIM negative. Several possible explanations may be advanced to account for these findings. First, the mutation(s) in these families may have altered the enzyme conformation such that its antigenic site or sites was not recognized by our anti-PBG-deaminase. It is, however, unlikely that a rabbit polyvalent antibody preparation (35, 36) would not recognize many, if not most, structurally altered proteins analogous to the experience with other enzyme deficiency disorders (37) . A more likely explanation would be a point mutation that resulted in a markedly unstable PBG-deaminase that would be rapidly degraded. Preliminary attempts to identify a highly unstable enzyme included studies of reticulocyte-enriched preparations and cultured lymphocytes and fibroblasts. Peripheral erythrocytes from two unrelated CRIM-negative AIP heterozygotes and two normal individuals were separated into age cohorts by discontinuous density gradient centrifugation (38) . Although the reticulocyte-rich fractions contained increased PBG-deaminase activity when compared with unfractionated circulating erythrocytes, the CRIMactivity ratio for the CRIM-negative AIP and normal reticulocytes were both essentially 1.0. In addition, rocket immunoelectrophoretic studies of cultured lymphocytes and fibroblasts (109 cells/sample) from CRIM-negative AIP heterozygotes and normal individuals did not reveal the presence of nonfunc-tional immunoreactive material, whereas cultured cells from a CRIM-positive AIP heterozygote had noncatalytic immunoreactive enzyme. Further investigation of the molecular nature of the CRIM-negative mutations may require the use of recombinant DNA techniques to obtain appropriate DNA probes to evaluate the possibility that the genetic defects in these AIP kindreds results from chain-terminating defects. mRNA processing defects, or partial or complete gene deletions analogous to those recently identified in the a-and,8p-thalassemias (39) (40) (41) (42) (43) .
In summary, these investigations have, for the first time, identified molecular genetic heterogeneity in AIP. The finding of stable enzyme-substrate intermediates for PBG-deaminase is unique among human enzymes, especially for a monomeric protein whose function is necessary for the production of such metabolically essential human molecules as the hemoglobins, cytochromes, and cobalamins. The finding of a genetically defective PBG-deaminase which can be detected immunologically, both as the free protein and as substrate-bound intermediates, provides the first molecular evidence for a structural gene mutation as the primary defect in AIP. Further investigation of the enzymatic defect in other AIP kindreds, using the immunologic techniques reported here, should provide additional insight into the molecular pathology and genetic heterogeneity ofthis dominantly inherited disorder of human heme biosynthesis.
